Pharmaxis closes IPO oversubscribed
29 October, 2003 by Melissa TrudingerSydney-based Pharmaxis closed its IPO yesterday, three days earlier than scheduled after strong demand from investors.
BresaGen in $5m bridging finance bid
29 October, 2003 by Graeme O'NeillAdelaide biotech BresaGen (ASX:BGN) is attempting to boost its cash reserves by up to AUD$5 million through a private placement of convertible preference shares, managed by PricewaterhouseCoopers Securities.
BioProspect buys trader to boost distribution prospects
29 October, 2003 by Graeme O'NeillBrisbane biopesticide developer BioProspect (ASX:BPO) has moved to establish itself as a significant player in the biotech business by acquiring agrochemical trader Tradewyns as a vehicle to distribute its products.
BTG International backs coeliac disease JV
28 October, 2003 by Melissa TrudingerA vaccine for coeliac disease is the focus of a joint venture between the Royal Melbourne Hospital, Melbourne Health and the Walter and Eliza Hall Institute of Medical Research (WEHI), in a project that has the backing of international VC group BTG International.
EpiTan reports "outstanding" results for Melanotan
28 October, 2003 by Graeme O'NeillMelbourne biotech EpiTan Ltd (ASX: EPT) has announced "outstanding" results from the Phase IIb clinical of its experimental tanning drug Melanotan - and says the data could be the subject of new patent applications.
Gradipore to refocus on commercialising its technology
28 October, 2003 by Melissa TrudingerAfter several tumultuous days that saw almost the entire board of directors replaced, bio-separations company Gradipore said today that it plans to focus on commercialising its technology for large-scale separations.
C3, Equipmed sign distribution agreements
27 October, 2003 by Melissa TrudingerPerth-based tissue engineering company Clinical Cell Culture (C3, ASX: CCE) has signed distribution agreements with Equipmed to distribute C3's CellSpray and ReCell products in Australia, excluding Western Australia, and New Zealand.
Panbio announces alliance with Adaltis
24 October, 2003 by Melissa TrudingerDiagnostics company Panbio has announced a strategic alliance with Canadian-based medical diagnostics instrumentation group Adaltis to develop automated diagnostic products.
Third patient implanted with Ventracor device
23 October, 2003 by Melissa TrudingerVentracor (ASX: VCR) has implanted its "artificial heart" device into a third patient as part of the pilot trial being conducted at the Alfred Hospital in Melbourne.
AtCor to enter US market
23 October, 2003 by Melissa TrudingerSydney-based devices company AtCor Medical is readying itself to make a major push into the US market with its range of cardiovascular diagnostic devices.
Virax wins US bioterrorism job
22 October, 2003 by Melissa TrudingerVirax (ASX:VHL) has received approval from the US State Department to participate in a collaboration to develop a modified smallpox vaccine.
Prima subsidiary claims arthritis treatment find
22 October, 2003 by Graeme O'NeillPrima BioMed (ASX:PRR) subsidiary Arthron believes it has found a new way of blocking the inflammatory reaction responsible for the crippling autoimmune disease rheumatoid arthritis.
Benitec claims 'multiple warhead' RNAi breakthrough
22 October, 2003 by Melissa TrudingerBenitec (ASX:BLT) has developed technology allowing simultaneous disabling of multiple genes through RNA interference.
Old fence to some, goldmine to BioProspect
21 October, 2003 by Graeme O'NeillAn ancient fence, its posts hewn from local trees, caught Matt Kealley's eye during a bioprospecting expedition in north Queensland's monsoonal woodlands a few years ago.
Visiomed receives TGA approval for MicroDERM Hair
21 October, 2003 by Melissa TrudingerPerth-based devices company Visiomed (ASX:VSG), formerly known as Xcell Diagnostics, has received TGA approval for a hair analysis system which uses the same computerised image analysis platform technology as its skin cancer diagnostic system.
